CSIMarket Company Name, Ticker, Suppliers, else..
 
Assertio Holdings inc   (NASDAQ: ASRT)
 
Price: $23.5000 $23.50 %
Day's High: $23.5 Week Perf: 0.00
Day's Low: $ 23.50 30 Day Perf: 0.26 %
Volume (M): 0 52 Wk High: $ 23.50
Volume (M$): $ 0 52 Wk Avg: $14.87
Open: $23.50 52 Wk Low: $8.61



 Market Capitalization (Millions $) 151
 Shares Outstanding (Millions) 6
 Employees 53
 Revenues (TTM) (Millions $) 102
 Net Income (TTM) (Millions $) -36
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0

Business Description


Assertio Holdings Inc. remains committed to delivering high-quality products and to meeting the needs of its customers.

In summary, Assertio Holdings Inc. is a specialty pharmaceutical company that develops and markets drugs for the treatment of various diseases. The company has a strong focus on quality control and regulatory adherence, and is committed to bringing new and innovative products to market. Despite facing some challenges in recent years, the company remains a leader in the pharmaceutical industry and is poised for future growth and success.


   Company Address: 100 South Saunders Road Lake Forest 60045 IL
   Company Phone Number: 419-7106   Stock Exchange / Ticker: NASDAQ ASRT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALKS   -3.85%    
AMRX   -1.74%    
BHC   -4.64%    
MNK   -39.2%    
TEVA   -2.38%    
VTRS   -0.18%    
• View Complete Report
   



Product Service News

Clinical Achievements Meet Financial Challenges Assertio Holdings’ Revealing Presentation on SYMPAZANs Real-...

Published Wed, Sep 10 2025 11:51 AM UTC

: Assertio Holdings, Inc., a prominent pharmaceutical company, is poised to present new findings from a real-world evidence study concerning SYMPAZAN (clobazam) Oral Film at the 150th Annual Meeting of the American Neurological Association. This study underscores the clinical and commercial potential of SYMPAZAN in addressing neurological conditions. However, despite this pr...
Management Changes

“Assertio Holdings: Navigating Leadership Changes and Clinical Innovations in Oncology After Revenue Challenges”,

Published Thu, Dec 12 2024 1:00 PM UTC

Assertio Holdings: Strategic Leadership Changes and Clinical Innovations in Oncology Amid ChallengesAssertio Holdings, Inc. a notable player in the pharmaceutical landscape, is gearing up for a pivotal shift under new leadership while navigating clinical innovations in oncology. The recent appointments of Paul Schwichtenberg as Chief Technology Officer (CTO) and Mary Pietryg...
Clinical Study

Assessing the Clinical and Economic Impact of Assertios Rolvedon A Balanced Approach to Innovation in Oncology Suppo...

Published Fri, Dec 13 2024 1:00 PM UTC

: The therapeutic landscape for oncology patients necessitates innovative solutions that ensure efficacy, safety, and practicality in the administration of supportive care treatments. In an effort to enhance patient convenience, Assertio Holdings Inc conducted a clinical study evaluating the same-day dosing efficacy of Rolvedon (eflapegrastim-xnst) against the traditional ne...
Stock Market Announcement

Clarifying the Narrative: Assertio Holdings and Rolvedon Address Misconceptions Over Financial Practices

Published Mon, Nov 11 2024 12:30 PM UTC

In the fast-paced landscape of pharmaceuticals, assertions can ripple through markets and affect not just individual companies, but entire sectors. Recently, a press release from Assertio Holdings drew attention, addressing what the company termed false and baseless claims regarding its accounting practices related to Rolvedon, its leading oncology product. On October 4, 202...
Product Service News

Assertio Holdings Navigating Financial Challenges and Strategic Growth Amid Sector Dynamics

Published Fri, Oct 4 2024 8:05 PM UTC

In recent developments, Assertio Holdings, Inc. has disclosed the approval of inducement grants in compliance with NASDAQ Listing Rule 5635(c)(4). While these inducement grants typically aim to attract and retain essential personnel, Assertio s latest financial performance sheds light on the considerable challenges the organization faces, particularly regarding its return on...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 1.48
Price to Sales (Expected) -
Price to Book 2
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.78
Working Capital Ratio 1.82
Leverage Ratio (MRQ) 1.79
Total Debt to Equity 0.52
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -4.02 $
Revenues (TTM) 15.88 $
Cash Flow (TTM) -
Cash 11.12 $
Book Value 11.76 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 1,927,509
Net Income per Employee (TTM) -673,396
Receivable Turnover Ratio (TTM) 1.06
Inventory Turnover Ratio (TTM) 1.16
Asset Turnover Ratio (TTM) 0.38

Profitability Ratios Current
Gross Margin (MRQ) 72.71 %
Operating Margin (MRQ) -185.95 %
Net Margin (MRQ) -189.83 %
Net Cash Flow Margin (MRQ) 236.42 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Assertio Holdings Inc's Segments
Total product sales net    89.58 % of total Revenue
ROLVEDON    4.96 % of total Revenue
INDOCIN products    34.69 % of total Revenue
Sympazan    25.97 % of total Revenue
SPRIX    13.79 % of total Revenue
Other products    10.16 % of total Revenue
Royalty revenue    4.38 % of total Revenue
Other revenue    6.04 % of total Revenue
Product sales net    89.58 % of total Revenue
CAMBIA Canada    4.03 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.